Aldeyra completes enrollment in Phase 3 dry eye trial of reproxalap; results expected in Q3 2024

Aldeyra Therapeutics, Inc.

Phase 3 dry eye chamber trial of 0.25% reproxalap enrolled 132 patients; primary endpoint is ocular discomfort.
Topline results expected in Q3 2024; NDA resubmission planned for H2 2024 contingent on positive data.
If approved, reproxalap may be first dry eye drug labeling chronic/acute symptom improvement and ocular redness reduction.
Four prior chamber trials showed reproxalap statistically superior to vehicle on ocular discomfort (p=0.0003).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.